Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 08 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding final approvals from the USFDA for various strengths of Dexamethasone Tablets. The approvals allow Zydus to manufacture and market these tablets, which are used to treat several medical conditions. The products will be produced at the company's facility in Baddi, Himachal Pradesh.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 08, 2024, titled "Zydus receives Final Approvals from the USFDA for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases